Kontopoulou, Konstantina; Nakas, Christos T.; Belai, Chrysoula; Papazisis, Georgios (2022). Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in immunocompromised adults in Greece: is a fourth dose necessary? Journal of medical virology, 94(10), pp. 5056-5060. Wiley-Liss 10.1002/jmv.27954
|
Text
Journal_of_Medical_Virology_-_2022_-_Kontopoulou_-_Antibody_Titers_After_a_Third_Dose_of_the_SARS_CoV_2_BNT162b2_Vaccine_in.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
Real-world data suggests that protection against COVID-19 declines a few months after vaccination, particularly in the elderly and immunocompromised individuals. Our study aimed to analyze the humoral response induced by a third supplemental dose of BNT162b2 vaccine in a mixed group of immunocompromised individuals by determining anti-spike (anti-S) IgG antibody titers at baseline (pre-third vaccine dose) and 4 weeks after the dose. Serum samples were obtained from a total group of 85 immunocompromised individuals (history of cancer: n=20, lymphoma: n=4, leukemia: n=3, transplant recipients: n=4, autoimmune disease: n=42, inflammatory disease: n=6, autoimmune diabetes type 1: n=6) all of whom had previously received a two-dose schedule of the vaccine. The average number of days between 2nd and 3rd dose was 139.6145 (±41.39071). The overall IgG GMCs four weeks post vaccination were increased by more than 35 times (fold change = 35. 30, p<0.001). Fold changes were not significantly correlated with underlying condition, age, sex nor with days between 2nd and 3rd dose. Considering the predominance of omicron variants in the current period and the results of studies showing a decrease in the effectiveness of the 3rd dose after 10 weeks we highly recommend a fourth dose to this vulnerable population group. This article is protected by copyright. All rights reserved.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry |
UniBE Contributor: |
Nakas, Christos T. |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0146-6615 |
Publisher: |
Wiley-Liss |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
27 Jun 2022 08:08 |
Last Modified: |
25 Jun 2023 00:25 |
Publisher DOI: |
10.1002/jmv.27954 |
PubMed ID: |
35739059 |
Uncontrolled Keywords: |
3rd dose BNT162b2 mRNA COVID-19 vaccine Greece SARS-CoV-2 antibody titers immunocompromised adults immunogenicity |
BORIS DOI: |
10.48350/170926 |
URI: |
https://boris.unibe.ch/id/eprint/170926 |
Actions (login required)
 |
Edit item |